If you strive to live an altruistic lifestyle, there are lots of ways to help out this Halloween. Here are some top tricks to make Halloween a treat for everyone.

Tutors help students young and old to better their education, improve their skills and gain more success in a field of their choice. Why should you consider becoming a tutor?

Pathway to Cures, the venture philanthropy fund of the National Bleeding Disorders Foundation is focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.  We carry out our work with volunteer expert advisors on our scientific advisory group, investment committee and board of directors.  Today we spotlight our investment committee, our process for determining what is presented to this committee and the criteria used in making NBDF’s Pathway to Cures investments.

NBDF is pleased to inform U.S.-based clinicians and other interested individuals of a new series of virtual educational opportunities organized by our friends at the Irish Haemophilia Society (IHS). The IHS is hosting a series of clinical webinars on key topics developed for healthcare providers practicing in the global bleeding disorders community. The six webinars will be held on Zoom during the months of October, November, and December.

How can you encourage the children in your life to be active and volunteer with their community? We have some ideas for how to get kids involved in giving back.

There are plenty of ways to get involved in your community this month. To get you started, we came up with six spooky-fun volunteering ideas for October.

Star Therapeutics recently announced new financing (totaling $125 million) that will help the San Francisco-based biotechnology company continue to develop their investigational von Willebrand disease therapy VGA039. The U.S. Food and Drug Administration granted Fast Track designation to the experimental subcutaneous von Willebrand disease therapy (VWD) in January 2025.

Novo Nordisk has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for Mim8 (denecimig), an investigational bispecific antibody therapy. The antibody promotes coagulation by binding two key proteins (factor IXa and factor X), essentially mimicking the function of the missing factor VIII in the clotting cascade. 

If you’re a bookworm, you know just how great reading can be. If you’re not, check it out, and see all the benefits books can give.

While it is generally understood that the social determinants of health (SDOH) are significant factors contributing to an individual’s overall health, research specific to SDOH and its impact upon the bleeding disorders community has been rather limited. Authors of a newly published paper sought to address this knowledge gap by conducting a pilot study on SDOH in bleeding disorders, and gain insight on how these factors pose challenges among underserved groups in the U.S. 

With the fall scholastic season now in full swing, we thought it would be a great time to share a few back-to-school resources to support students, families, and school personnel. This edition of the Resource Roundup features articles, educational videos and fact sheets, all of which speak to both school-based topics and bleeding disorders.

Make this season about more than just pumpkin spice lattes and costumes. Check out some of these ideas on how you can give back this month.

Five people who are inspired by the bleeding disorders community are lacing up for an immense physical challenge: running the TCS New York City Marathon on November 2, 2025. They’ll be running across the Verrazano-Narrows Bridge, through the streets of Brooklyn and Queens, and down 5^th Avenue in Manhattan – and each step will help NBDF’s mission of helping people and families living with bleeding disorders to thrive.

Decades of advocacy spearheaded by the World Federation of Hemophilia (WFH) have resulted in a victory for the global bleeding disorders community. The World Health Organization (WHO) Model List of Essential Medicines (EML) has been updated to include safer and more effective medicines for the treatment of bleeding disorders. 

Values and beliefs instilled now flourish into actions later. What can you do to instill philanthropic values in your children? To get you started, here are six ways to teach your child about giving.

The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for VONVENDI®, which expands its indication to include prophylaxis use to reduce the frequency of bleeding episodes in adults with von Willebrand disease (VWD), including those with type 1 and 2 disease, and for on-demand and perioperative management of bleeding in pediatric patients with VWD.

Federal: 

2025 Bleeding Disorders Conference 

NBDF wrapped up another successful Bleeding Disorders Conference. The policy team was busy with sessions on blood and product safety, access to insurance, and sharing updates on what’s happening in Washington, DC. This year there was also a session dedicated to NBDF’s advocacy efforts focused on women and girls. You can see the highlights from this year’s conference here. 

Pathway to Cures, NBDF’s venture philanthropy fund, is an investor in Be Biopharma, Inc., a clinical-stage company developing engineered B cell medicines.  Be Biopharma recently announced the first participant treated with their therapy BE-101 in the BeCoMe-9 Phase 1/2 clinical trial. 

What is BE-101?

If you’re looking to celebrate this multicolor season in style with your family, check out these fun fall adventures you need to go on this year.

Sometimes we all need to feel like a kid again. If you’re tired of adulthood and want to rewind the clock, check out these six activities to relive those childhood memories.

Studies have found that volunteering can positively impact both your body and your mind. Here are a few ways doing good in your community can do some good for yourself!

Gene therapy was once hailed as the transformative breakthrough for hemophilia—the long-awaited cure that would change everything. But reality has been more nuanced, and many people in the community have been hesitant to embrace it. Some pharmaceutical companies have canceled their gene therapy programs, removing the treatment from the market. What this means for the future of innovation was what Friday's panel at NBDF's Bleeding Disorders Conference set out to explore.

Research, Evidence-based Practice, and QI: A Roadmap for Multidisciplinary Teams

Healthcare providers face a sobering reality: 400,000 unintended patient deaths occur annually, with adverse events affecting one in four hospital admissions. Yet these tragedies aren't due to incompetence—they can result from poorly-designed systems and inconsistent practices. Perhaps most striking, only 20-30% of healthcare decisions are based on solid evidence.

The last day of the 77th Annual Bleeding Disorders Conference brought inspiration at every turn—from sessions on data-driven research to stories from everyday heroes and celebrating leaders who make a difference. But the night was all about connection and fun.

The evening turned into a true celebration. With bohemian flair, live music, family games, great food, and plenty of dancing, the Final Night Event brought the energy and joy that made it the perfect ending to the conference.

Breakthrough sessions, hands-on workshops, and time together in community—Friday had it all. The day was full of learning, laughter, and moments that brought people closer.

One of the most meaningful parts of the Bleeding Disorders Conference was the chance for people to gather in spaces that reflected their identities and experiences. This year, NBDF hosted a series of intersectional sessions and networking hours that gave attendees the opportunity to sit together, share stories, and learn from one another. These gatherings honored the richness of our community while creating supportive spaces where everyone felt seen.

At NBDF's “Unlocking the Clotting Cascade,” at NBDF’s Bleeding Disorders Conference, attendees discovered that sometimes the best way to understand complex biology is to get your hands dirty—or in this case, get crafty with cotton balls and straws. In a hands-on workshop, participants rolled up their sleeves to build the clotting process piece by piece using everyday craft supplies.

We all set goals, and we don't always meet them. But what if there was a better way of thinking about goals? Rise and Thrive: Empowered Goal Setting, aimed to help attendees achieve their goals by thinking about them in a new way.

The workshop was hosted by Brendan Hayes, NBDF’s senior director of education, and summer intern Devin Boyle and was packed with practical tips and hands-on activities designed to help participants make real progress in their lives.

The treatment horizon for bleeding disorders looks remarkably different than it did just a few years ago. From nerve stimulation devices to injections every two months, from experimental pills to designer antibodies, the future of bleeding disorders care is unfolding with possibilities that extend far beyond traditional factor replacement. The popular, “Advancements in Treatments forn Bleeding Disorders,” took a look into the future.

Expanding Beyond Hemophilia

Check out the highlights in photos from day one!

Defining Hope, Strength, and Infinite Possibility

Community member Ryan Warnall's voice filled the auditorium as he performed "The Impossible Dream," setting an emotional tone that would define the National Bleeding Disorders Foundation (NBDF) Opening Session on Thursday, August 21, 2025. His performance captured something essential about this community: a group that has repeatedly turned the impossible into reality, from fighting for a safer blood supply to developing treatments that seemed beyond hope decades ago.

NBDF’s Bleeding Disorders Conference welcomed many people new to bleeding disorders, and offered preconference sessions to help these new attendees acquire some basic knowledge to assist them on their education journey throughout the conference. “Hemophilia Treatment Landscape,” on Thursday, August 21, 2025, gave attendees a comprehensive overview in the current ways of treating hemophilia. 

Why does treatment for women and girls with bleeding disorders lag so far behind treatment for men, and what can we do about it? These were the central questions of “Women Bleed Too: Addressing the Blind Spots,” on Thursday, August 21, at NBDF’s Bleeding Disorders Conference.

On Thursday evening, from 6:30 to 7:30 pm in the Exhibit Hall, NBDF held a special “Meet the Poster Abstract Authors” session, featuring the 47 poster abstract approved for display during this year’s BDC in Aurora, Colorado. All conference attendees had an opportunity to view the posters and meet with the authors directly.  The authors represent universities, pharmaceutical companies, hemophilia treatment centers, or other bleeding disorders organizations in the US or beyond.   Abstracts were initially submitted to NBDF in spring and then assessed by a panel of experts.

The National Bleeding Disorders Foundation’s (NBDF) 77th Annual Bleeding Disorders Conference (BDC) is finally here. We like to think of this as a family reunion – whether you’re new to the community or have been attending for years, you’ll be welcomed with open arms.

Welcome to the Heart of Our Community

For people who have just discovered that they have VWD, the diagnosis can seem overwhelming. The Thursday pre-conference session, “VWD: Your Masterclass in VWD Insights and Community,” sponsored by CSL Behring, was designed to give attendees a firm understanding of the bleeding disorder, current treatments, and what future therapies are being studied.

Big news! NBDF’s Pathway to Cures portfolio company Spark Biomedical was selected by Wellcome Leap as an awardee of “The Missed Vital Sign” worldwide program.

Fundraisers are an important way to give back to your school and raise money to support causes you care about. However, fundraisers aren’t the only way to get involved.

Concizumab-mtci (Alhemo®) has received approval from the US Food and Drug Administration (FDA) as a once-daily prophylactic treatment for patients aged 12 years and older with hemophilia A or B without inhibitors.

This new approval results in an expanded indication for Concizumab-mtci, which was initially approved by the FDA in December 2024 for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.

Whether they’re familial, romantic or platonic, relationships are vital to beneficial and stable lives. So how can we learn to build positive and enriching relationships?

Explore the latest updates on federal budget reconciliation, healthcare lawsuits, and state-level policy changes impacting bleeding disorders. Learn how NBDF is advocating for access, funding, and patient protections.

Federal: 

At the turn of the 21st century, there was great excitement and anticipation of gene therapy as a ‘curative’ treatment for hemophilia A and B patients, particularly among those with moderate-to-severe forms of the disease. However, a recent forum piece in the journal Research & Practice in Thrombosis & Haemostasis (RPTH) offers some reasons why the overall commercial uptake of these therapies has been relatively modest, as lingering questions over long-term efficacy (in the case of hemophilia A) and longer-term safety of these first-generation gene therapies.

This August, we celebrate National Water Quality Month. How can you have an impact on water quality?

Background 

According to multiple news outlets, the U.S. Centers for Medicare & Medicaid Services (CMS) in mid-July provided the personal data of millions of Medicaid enrollees to the U.S. Department of Homeland Security (DHS), as part of the Administration’s ongoing immigration enforcement efforts. This action marked a change from longstanding policy and previous practice barring such information sharing. 

Clinical stage biotechnology Be Biopharma, Inc. recently announced that the first hemophilia B patient has been treated with a single intraveneous dose of their investigational cell therapy, BE-101. The ongoing BeCoMe-9 Phase 1/2 study is evaluating the safety and efficacy of BE-101 in adults with moderately severe to severe hemophilia B.

Pathway to Cures, the venture philanthropy fund of the National Bleeding Disorders Foundation, is delighted to name Sylvia Fong, PhD as a member of its Scientific Advisory Group. Dr.

The National Bleeding Disorders Foundation’s (NBDF) National Research Blueprint (NRB), launched in 2020, has a new name: the Bleeding Disorders Research Collaborative.  

For individuals and their families, the words “You need a new organ” are earth-shattering. Luckily, we can make a difference.

Newly published findings suggest positive results from a late-stage clinical trial on a much-needed treatment option for young people with persistent or chronic primary immune thrombocytopenia (ITP).

How can you live an altruistic lifestyle when negativity is on your mind? Today we've got the answers as we share six tips to help train your brain to be more positive.